Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2011 Jan 4;104(1):1-3.
doi: 10.1038/sj.bjc.6606023.

Targeting IGF-1R: throwing out the baby with the bathwater?

B Basu, D Olmos, J S de Bono
Editorial

Targeting IGF-1R: throwing out the baby with the bathwater?

B Basu et al. Br J Cancer. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Johann de Bono has served as a paid consultant for Pfizer, Genentech, Novartis, Astellas, Boehringer Ingelheim, Merck, and AstraZeneca.

Comment on

References

    1. Frystyk J (2007) Utility of free IGF-I measurements. Pituitary 10(2): 181–187 - PubMed
    1. Gualberto A, Dolled-Filhart M, Gustavson M, Christiansen J, Wang YF, Hixon ML, Reynolds J, McDonald S, Ang A, Rimm DL, Langer CJ, Blakely J, Garland L, Paz-Ares LG, Karp DD, Lee AV (2010) Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin Cancer Res 16(18): 4654–4665 - PMC - PubMed
    1. Gualberto A, Hixon ML, Karp DD, Li D, Green S, Dolled-Filhart M, Paz-Ares LG, Novello S, Blakely J, Langer CJ, Pollak MN (2010b) Pre-treatment levels of circulating free IGF-1 identity NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer 104: 68–74 - PMC - PubMed
    1. Han JY, Choi BG, Choi JY, Lee SY, Ju SY (2006) The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer. Lung Cancer 54(2): 227–234 - PubMed
    1. Jassem J, Langer CJ, Karp DD, Mok T, Benner RJ, Green SJ, Park K, Novello S, Strausz J, Gualberto A (2010) Randomized, open label, phase III trial of figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). J Clin Oncol (Meet Abstr) 28(Suppl 15): 7500

MeSH terms